- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06284317
IIB-IIIB기(N2) 절제 가능한 NSCLC 환자에서 신보강 화학요법과 Durvalumab을 병용한 후 보조 Durvalumab을 추가하는 이점을 평가하기 위한 국제, 다기관, 공개 무작위 3상 시험 (ADOPT-lung)
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations.
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Heidi Roschitzki, PhD
- 전화번호: +41 31 511 94 00
- 이메일: heidi.roschitzki@etop.ibcsg.org
연구 연락처 백업
- 이름: Susanne Roux
- 전화번호: +41 31 511 94 00
- 이메일: ADOPT-lung@etop.ibcsg.org
연구 장소
-
-
-
Amsterdam, 네덜란드
- 모병
- NKI
-
연락하다:
- Willemijn Theelen
- 이메일: w.theelen@nki.nl
-
Utrecht, 네덜란드
- 모병
- UMCU
-
연락하다:
- W.K. de Jong
- 이메일: w.k.dejong-9@umcutrecht.nl
-
-
-
-
-
Anderlecht, 벨기에
- 모병
- Institut Jules Bordet - HUB
-
연락하다:
- Mariana Brandao
- 이메일: mariana.brandao@hubruxelles.be
-
Antwerp, 벨기에
- 모병
- Antwerp University Hospital
-
연락하다:
- Reinier Wener
-
-
-
-
-
Baden, 스위스
- 아직 모집하지 않음
- Kantonsspital Baden
-
연락하다:
- Sacha Rothschild
- 이메일: sacha.rothschild@ksb.ch
-
Basel, 스위스
- 모병
- Universitätsspital Basel
-
연락하다:
- David König
- 이메일: david.koenig@usb.ch
-
Bellinzona, 스위스
- 아직 모집하지 않음
- Eoc - Iosi
-
연락하다:
- Martina Imbimbo
- 이메일: martina.imbimbo@eoc.ch
-
Bern, 스위스
- 모병
- Inselspital Bern
-
연락하다:
- Sabine Schmid
- 이메일: sabine.schmid@insel.ch
-
Fribourg, 스위스
- 모병
- HFR Hôpital Fribourgeois
-
연락하다:
- Adrienne Bettini
- 이메일: Adrienne.Bettini@h-fr.ch
-
Lausanne, 스위스
- 아직 모집하지 않음
- CHUV
-
연락하다:
- Hasna Bouchaab
- 이메일: hasna.bouchaab@chuv.ch
-
Sankt Gallen, 스위스
- 모병
- Kantonsspital St.Gallen
-
연락하다:
- Martin Früh
- 이메일: Martin.frueh@kssg.ch
-
Winterthur, 스위스
- 모병
- Kantonsspital Winterthur
-
연락하다:
- Laetitia Mauti
- 이메일: laetitia.mauti@ksw.ch
-
Zurich, 스위스
- 아직 모집하지 않음
- University Hospital Zurich
-
연락하다:
- Isabelle Opitz
- 이메일: isabelle.schmitt-opitz@usz.ch
-
-
-
-
-
Dublin, 아일랜드
- 모병
- Beaumont Hospital
-
연락하다:
- Jarushka Naidoo
- 이메일: jarushkanaidoo@beaumont.ie
-
Dublin, 아일랜드
- 모병
- St James's Hospital
-
연락하다:
- Patrick Forde
- 이메일: pforde1@jhmi.edu
-
-
-
-
-
Talinn, 에스토니아
- 모병
- North Estonia Medical Centre Foundation
-
연락하다:
- Kersti Oselin
- 이메일: Kersti.Oselin@regionaalhaigla.ee
-
-
-
-
-
Cardiff, 영국
- 모병
- Velindre University NHS Trust
-
연락하다:
- Paul Shaw
-
Glasgow, 영국
- 아직 모집하지 않음
- Beatson West of Scotland Cancer Centre NHS Greater Glasgow and Clyde
-
연락하다:
- Nicola Steele
-
London, 영국
- 모병
- Barts Health NHS Trust
-
연락하다:
- Adam Januszewski
- 이메일: adam.januszewski@nhs.net
-
London, 영국
- 아직 모집하지 않음
- Royal Marsden Hospital (Chelsea)
-
연락하다:
- Sanjay Popat
- 이메일: sanjay.popat@rmh.nhs.uk
-
London, 영국
- 아직 모집하지 않음
- Royal Marsden Hospital (Sutton)
-
연락하다:
- Sanjay Popat
- 이메일: sanjay.popat@rmh.nhs.uk
-
Maidstone, 영국
- 모병
- Maidstone and Tunbridge Wells NHS Trust
-
연락하다:
- Riyaz Shah
- 이메일: riyaz.shah@nhs.net
-
Manchester, 영국
- 모병
- Wythenshawe Hospital, Manchester University NHS Foundation Trust
-
연락하다:
- Igor Randulfe
- 이메일: yvonne.summers@nhs.net
-
-
-
-
-
Vienna, 오스트리아
- 모병
- Wien AKH
-
연락하다:
- Clemens Aigner
- 이메일: clemens.aigner@meduniwien.ac.at
-
-
-
-
-
Alessandria, 이탈리아
- 아직 모집하지 않음
- SS Antonio e Biagio e Cesare Arrigo Hospital
-
연락하다:
- Pier Luigi Piovano
- 이메일: plpiovano@ospedale.al.it
-
Padova, 이탈리아
- 모병
- Istituto Oncologico Veneto
-
연락하다:
- Laura Bonnano
- 이메일: laura.bonanno@iov.veneto.it
-
Perugia, 이탈리아
- 아직 모집하지 않음
- Perugia Hospital
-
연락하다:
- Giulio Metro
- 이메일: giulio.metro@ospedale.perugia.it
-
Rome, 이탈리아
- 모병
- Istituto Nazionale Tumori "Regina Elena"
-
연락하다:
- Landi Lorenza
- 이메일: lorenza.landi@ifo.it
-
Siena, 이탈리아
- 아직 모집하지 않음
- AOUS Policlinico Le Scotte
-
연락하다:
- Michele Maio
- 이메일: mmaiocro@gmail.com
-
Verona, 이탈리아
- 모병
- Universita di Verona - Department of Medicine
-
연락하다:
- Lorenzo Belluomini
- 이메일: lorenzo.belluomini@univr.it
-
-
-
-
-
Angers, 프랑스
- 모병
- CHU Angers
-
연락하다:
- Youssef Oulkhouir
- 이메일: Youssef.Oulkhouir@chu-angers.fr
-
Bordeaux, 프랑스
- 모병
- Institut Bergonié
-
연락하다:
- Sophie Cousin
- 이메일: s.cousin@bordeaux.unicancer.fr
-
Le Mans, 프랑스
- 모병
- Le Mans - CHG
-
연락하다:
- Camille Guguen
- 이메일: cguguen@ch-lemans.fr
-
Lyon, 프랑스
- 모병
- Lyon - Centre Léon Bérard
-
연락하다:
- Maurice Pérol
- 이메일: maurice.perol@lyon.unicancer.fr
-
Metz, 프랑스
- 모병
- Hôpital Robert Schuman - Groupe UNEOS
-
연락하다:
- Lucile Roussel
-
-
-
-
New South Wales
-
Camperdown, New South Wales, 호주
- 아직 모집하지 않음
- Chris O'Brien Lifehouse
-
연락하다:
- Malinda Itchins
-
Penrith, New South Wales, 호주
- 모병
- Nepean Hospital
-
연락하다:
- Deme Karikios
-
St Leonards, New South Wales, 호주
- 모병
- Royal North Shore Hospital
-
연락하다:
- Malinda Itchins
-
-
Queensland
-
Woolloongabba, Queensland, 호주
- 아직 모집하지 않음
- Princess Alexandra Hospital
-
연락하다:
- Kenneth O'Bryne
-
-
South Australia
-
Bedford Park, South Australia, 호주
- 아직 모집하지 않음
- Flinders Medical Centre
-
연락하다:
- Chris Karapetis
-
-
Tasmania
-
Hobart, Tasmania, 호주
- 아직 모집하지 않음
- Royal Hobart Hospital
-
연락하다:
- Rebecca Tay
-
-
Victoria
-
Box Hill, Victoria, 호주
- 모병
- Eastern Health
-
연락하다:
- Phillip Parente
-
Melbourne, Victoria, 호주
- 모병
- Alfred Hospital
-
연락하다:
- Maggie Moore
-
Parkville, Victoria, 호주
- 모병
- Peter MacCallum Cancer Centre
-
연락하다:
- Benjamin Solomon
-
-
Western Australia
-
Nedlands, Western Australia, 호주
- 아직 모집하지 않음
- Sir Charles Gairdner Hospital
-
연락하다:
- Samantha Bowyer
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria for enrolment:
- Histologically confirmed NSCLC.
- Stage IIB-IIIB (T1-4 N0-2) according to 8th edition of the TNM staging system of lung cancer.
Stage III assessment should include samples of lymph nodes at levels 4, bilaterally, and level 7 to rule out stage IIIB N3 disease.
T4 tumours will only be eligible if they are defined as T4 based only on their size (>7cm); any other reason will be considered ineligible.
- Known PD-L1 status, as tested locally using a validated assay. To ensure comparability of results, it is strongly encouraged that PD-L1 testing is done with the Ventana PD-L1 (SP263) assay.
- Absence of EGFR mutation or ALK translocation, as tested locally.
- Primary tumour resectable and functionally operable as assessed per local multidisciplinary tumour board (cardiac evaluation, pulmonary function and diffusion capacity, comorbidity).
- Adequate haematological function:
Haemoglobin ≥90 g/L, Absolute neutrophil count (ANC) ≥1.0× 109/L, Platelet count ≥75× 109/L.
- Adequate renal function: Measured creatinine clearance (CL) >40 mL/min or calculated CL >40 mL/min calculated by the Cockcroft-Gault.
- Adequate liver function: ALT and AST ≤2.5× institutional ULN, Total serum bilirubin ≤1.5× institutional ULN (patients with Gilbert's syndrome may be allowed to be enrolled after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Age ≥18 at the time of enrolment.
- Body weight >30 kg.
- Life expectancy of at least 12 weeks.
- Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test at screening before enrolment. Pregnancy test must be repeated within 3 days before the first dose of protocol treatment.
- Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Eligibility Criteria for randomisation:
- Surgical resection must have been completed. Note: Participants who have had only had segmentectomy or wedge resections are not eligible for randomisation.
- Patients must have complete resection: R0 or R1 resection.
- Patients must be fit to receive adjuvant treatment with durvalumab.
- Patients must have no evidence of metastatic disease as assessed by CT scan.
- Documentation of pathological response as per local review must be available.
Exclusion Criteria for enrolment:
- T4 with invasion of heart, great vessels, carina, trachea, oesophagus, or spine.
- Any previous or concurrent treatments for NSCLC.
- Any previous immunotherapy.
- Major surgical procedure (as per investigators assessment) within 28 days before enrolment.
- History of allogenic organ transplantation.
- Active or prior documented autoimmune disease or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:
Patients with vitiligo or alopecia. Patients with type I diabetes. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
Any chronic skin condition that does not require systemic therapy. Patients without active disease in the last 5 years may be included but only after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.
Patients with celiac disease controlled by diet alone.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), or serious chronic gastrointestinal conditions associated with diarrhoea.
- Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- History of another primary malignancy except for:
Malignancy treated with curative-intent and with no known active disease 5 years before the first dose of durvalumab and of low potential risk for recurrence.
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
Adequately treated carcinoma in situ without evidence of disease.
- History of leptomeningeal carcinomatosis.
- History of active primary immunodeficiency.
- Active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HbsAg) or HBV core antibody (anti-HBc).
Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HbsAg) are eligible.
Participants positive for HCV antibody are only eligible if polymerase chain reaction is negative for HCV RNA.
- Known HIV infection that is not well-controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 3 months, CD4+ count of 500 cell per mm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 3 months on the same anti-HIV medication.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent.
Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab.
Note: Patients in the ADOPT-lung trial, should not receive live vaccine whilst receiving durvalumab and for up to 30 days after the last dose.
Concurrent enrolment in another interventional clinical trial.
- Known allergy or suspected hypersensitivity to durvalumab or its excipients.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
- Female patients who are pregnant or in the period of lactation.
- Female patients of childbearing potential and sexually active men who are not willing to use a highly effective contraceptive method during the trial until at least 90 days after the last dose of protocol treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Durvalumab
Protocol treatment in the adjuvant phase consists of adjuvant durvalumab |
Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery. |
|
간섭 없음: Observation
Observation only |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease-free survival (DFS)
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase. DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
DFS in patients with pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Overall survival (OS) in patients with/without pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). OS is defined as the time from the date of randomisation until death from any cause. Censoring (for patients who are not reported as having died) will occur at the date when they were last known to be alive. Patients without post-randomisation information will be censored at the date of randomisation (plus 1 day). OS will be assessed in patients with/without pCR. |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
DFS in patients with/without ctDNA clearance
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Time to recurrence (TTR) in patients with/without pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). TTR is defined as the time from the date of randomisation until disease recurrence. Censoring (for patients without recurrence) will occur at the date of the last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). TTR will be assessed in patients with/without pCR. |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Time to treatment discontinuation (TTD) in patients with/without pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Toxicity according to CTCAE v5.0
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). All safety parameters will be summarised in tables to evaluate the toxicity/safety profile of the protocol treatment based on:
|
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Correlation between ctDNA clearance and DFS
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation between ctDNA clearance and OS
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation between ctDNA clearance and initial PD-L1 assessment
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Outcome (event-free survival)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Outcome (EFS) in patients with patients with either
|
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation of Outcome Disease-free survival (DFS)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Correlation of Outcome (DFS) in patients with longitudinal ctDNA assessment |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation of Outcome Overall survival (OS)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Correlation of Outcome (OS) in patients with longitudinal ctDNA assessment |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
pCRDescription of patients entering each phase (e.g., % surgery, % randomised)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
pCRDescription of patients entering each phase (e.g., % surgery, % randomised) |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
공동 작업자 및 조사자
협력자
수사관
- 연구 의자: Solange Peters, MD-PhD, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
- 연구 의자: Sabine Schmid, MD, Inselspital, Universitätsspital Bern, 3010 Bern, Switzerland
- 연구 의자: Paul Van Schil, MD-PhD, Antwerp University Hospital, Antwerp, Belgium,
- 연구 의자: Stephen Finn, MD-PhD, St. James's Hospital, Dublin 8, Ireland
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .